Ozempic, semaglutide
Named-patient access overview. Ozempic is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
This page is informational, not medical advice. Always work with a licensed treating physician on prescribing decisions. Ozempic is approved for type 2 diabetes, not weight loss; the obesity indication is held by a separate semaglutide product (Wegovy).
About Ozempic
Ozempic is the brand name for semaglutide injection, manufactured by Novo Nordisk. The US Food and Drug Administration approved Ozempic in December 2017 for the treatment of type 2 diabetes mellitus in adults. It is a once-weekly subcutaneous injection delivered through a multi-dose prefilled pen. Ozempic shares its active ingredient, semaglutide, with Novo Nordisk's oral product Rybelsus (T2DM) and its higher-dose injectable Wegovy (chronic weight management). The 3 are not interchangeable, and Ozempic is specifically the type 2 diabetes brand.
The clinical evidence base for semaglutide has expanded significantly since launch, including cardiovascular outcomes data showing reduction in major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Mechanism of action
Glucagon-like peptide-1, or GLP-1, is a gut-derived hormone the body releases in response to eating. It triggers insulin secretion in a glucose-dependent way, suppresses glucagon, slows gastric emptying, and signals satiety to the brain. Native GLP-1 breaks down within minutes. Semaglutide is engineered to resist that breakdown, allowing for once-weekly dosing.
In plain terms: the medicine mimics the body's own post-meal hormone, but with a much longer half-life. Blood sugar control improves through better-timed insulin release, and many patients also experience reduced appetite and modest weight reduction as side effects of the mechanism.
FDA-approved indications
Ozempic is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also approved to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease. It is not approved for the treatment of obesity. It is not approved for type 1 diabetes. It is not approved for diabetic ketoacidosis. Patients seeking semaglutide for weight management should discuss Wegovy with their treating physician, which is a separate product at higher dosing.
Dosing and administration
Ozempic is administered as a subcutaneous injection once weekly, on the same day each week, at any time of day, with or without meals. The standard starting dose is 0.25 mg weekly for 4 weeks (this is a tolerability dose only, not effective for glycemic control). The dose is then increased to 0.5 mg weekly. Further escalation to 1 mg weekly or 2 mg weekly is available if additional glycemic control is needed. Refrigerated storage between 36 and 46 degrees Fahrenheit is required before first use. After first use, the pen can be kept at room temperature or refrigerated for up to 56 days before disposal.
Side-effect profile
The most commonly reported side effects are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, and constipation. These are usually dose-related and tend to ease over the first several weeks. Slower dose titration helps. More serious but less common effects include pancreatitis, diabetic retinopathy complications (particularly in patients with pre-existing retinopathy and rapid glycemic improvement), gallbladder disease, and acute kidney injury (often in the setting of dehydration from gastrointestinal side effects).
Ozempic carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2. The right monitoring cadence is always a conversation between patient and treating physician.
Why international patients seek Ozempic cross-border
Global semaglutide demand has chronically outrun supply since 2022. In many of the countries Reserve Meds serves, Ozempic is either locally unavailable for weeks at a time, rationed to existing patients on therapy, or available only through narrow specialist pathways. Patients with a clear US-label type 2 diabetes indication, an established response to semaglutide, and a treating physician's prescription frequently find themselves with no continuous local route.
Reserve Meds will not coordinate Ozempic for off-label weight-management requests where Wegovy is the FDA-approved option. Every Ozempic case is reviewed for clinical appropriateness, sourced from DSCSA-compliant US specialty wholesalers with full serialization and unbroken cold chain, and routed through the destination country's lawful import framework. We do not handle controlled substances. We do not sell direct to consumers.
Start a request for Ozempic
Submit a 60-second intake. Our clinical team will review your case and respond as our first cohort opens with case-specific feasibility, a country pathway, an indicative timeline, and a formal quote. Reserved for you.
Access by country
Reserve Meds publishes a detailed country deep-dive for Ozempic in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.